Insights about Giant Cell Arteritis (GCA) pathogenesis (IL-6-IL17 or IL12-INF-γ cytokine cluster, Notch-Notch ligand), clinical phenotypes (large vessel, cranial type), diagnostic procedures (biopsy, US, MRI, PET/CT), treatment recommendations (BSR, EULAR), long-standing glucocorticoid complications (up to 80% of GCA patients), disease relapses (∼50% at the first year) and novel treatment approaches such as tocilizumab (GiACTA trial, with sustained remission up to 56% up to week 52), were presented by Dr Pinelopi Konstantopoulou. This evidence concerns the gene IL6 and temporal arteritis.